Identification of Immunohistochemical Prognostic Markers for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

 

 Buy Article Permissions and Reprints All articles of this category

Abstract

Background: Although aggressive resection of pulmonary metastases prolongs the survival of patients with metastatic colorectal cancer, there is a need for predictive pathologic parameters to understand the key molecular events of metastatic progression. The aim of this study was to verify immunohistochemical markers in addition to established clinical parameters after surgery. Methods: From our subset of patients undergoing resection of pulmonary metastases from metastatic colorectal carcinoma, we analyzed 39 patients (23 men and 16 women) between 2003 and 2007. Only patients who met the criteria for a potentially curative operation were included. All patients were analyzed with regard to age and sex, primary tumor location, stage of the primary tumor, history of hepatic metastases, number of pulmonary metastases, pre-thoracotomy carcinoembryonic (CEA) serum antigen level, and the presence of thoracic lymph node metastasis. Furthermore, we immunohistochemically investigated the expression of vascular endothelial growth factor (VEGF)-D, FBJ murine osteosarcoma viral oncogene homolog B (FOS‐B), and melanoma antigen (MAGE)-A in the surgical specimens of pulmonary metastatic lesions. Results: The overall 3-year survival was 50.6 %. A significantly longer survival was observed with multivariate analysis in patients with a pre-thoracotomy serum carcinoembryonic antigen level of no more than 4.2 ng/mL (p = 0.001), and Dukes stage A or B primary tumor (p = 0.001). A significantly longer recurrence-free survival was observed with multivariate analysis in patients without thoracic lymph node involvement compared to patients with pulmonary and/or mediastinal lymph node metastases (p = 0.006). The stage of the primary tumor remained significant (p = 0.029), and FOS‐B expression in tumor cells showed a trend towards favorable recurrence-free survival after pulmonary metastasectomy (p = 0.059). No statistically significant difference was found in the overall survival rate or recurrence-free survival rate of patients with expression of VEGF‐D or MAGE‐A antigen in pulmonary metastatic tumor cells. Conclusions: Our results suggest that in addition to clinically prognostic factors, FOS‐B expression has a debatable impact on patient survival. We conclude that the evaluation of molecular and clinical prognostic parameters at the time of pulmonary metastasectomy offers a greater understanding of the metastatic process and provides important information for patient selection.

References

• 1 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.  Ann Thorac Surg. 2007;  84 (1) 324-338
  CrossrefPubMedGoogle Scholar
• 2 Treasure T, Utley M, Hunt I. When professional opinion is not enough.  BMJ. 2007;  334 (7598) 831-832
  CrossrefPubMedGoogle Scholar
• 3 Pfannschmidt J. Chirurgie der Lungenmetastasen – Klinische und molekularbiologische Prognoseparameter [Habilitation]. Heidelberg; Ruprecht-Karls-Universität Heidelberg 2006
  PubMedGoogle Scholar
• 4 Abel U, Berger J, Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors.  Methods Inf Med. 1984;  23 (3) 154-156
  PubMedGoogle Scholar
• 5 Kaplan E, Meier P. Non-parametric estimation from incomplete observations.  J Am Stat Assoc. 1958;  53 457-481
  CrossrefPubMedGoogle Scholar
• 6 Peto R, Peto J. Asymptomatically efficient rank invariant test procedures.  JR Stat Soc A. 1972;  135 185-198
  PubMedGoogle Scholar
• 7 Cox D. Regression models and life-table (with discussion).  JR Stat Soc B. 1972;  34 187-220
  PubMedGoogle Scholar
• 8 Melloni G, Doglioni C, Bandiera A et al. Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.  Ann Thorac Surg. 2006;  81 (6) 2008-2013
  CrossrefPubMedGoogle Scholar
• 9 Shiono S, Ishii G, Nagai K et al. Histopathologic prognostic factors in resected colorectal lung metastases.  Ann Thorac Surg. 2005;  79 (1) 278-282 discussion 283
  CrossrefPubMedGoogle Scholar
• 10 Shiono S, Ishii G, Nagai K et al. Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis.  Eur J Surg Oncol. 2006;  32 (3) 308-309
  CrossrefPubMedGoogle Scholar
• 11 Kayser K, Zink S, Andre S et al. Primary colorectal carcinomas and their intrapulmonary metastases: clinical, glyco-, immuno- and lectin histochemical, nuclear and syntactic structure analysis with emphasis on correlation with period of occurrence of metastases and survival.  Apmis. 2002;  110 (6) 435-446
  CrossrefPubMedGoogle Scholar
• 12 Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Watanabe G. Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor.  J Thorac Cardiovasc Surg. 2004;  128 (4) 517-522
  CrossrefPubMedGoogle Scholar
• 13 Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis.  Nat Rev Cancer. 2005;  5 (9) 735-743
  CrossrefPubMedGoogle Scholar
• 14 Skobe M, Hawighorst T, Jackson D G et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.  Nat Med. 2001;  7 (2) 192-198
  CrossrefPubMedGoogle Scholar
• 15 Stacker S A, Caesar C, Baldwin M E et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.  Nat Med. 2001;  7 (2) 186-191
  CrossrefPubMedGoogle Scholar
• 16 Mandriota S J, Jussila L, Jeltsch M et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.  Embo J. 2001;  20 (4) 672-682
  CrossrefPubMedGoogle Scholar
• 17 Hasegawa H, Mori M, Haraguchi M, Ueo H, Sugimachi K, Akiyoshi T. Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma.  Arch Pathol Lab Med. 1998;  122 (6) 551-554
  PubMedGoogle Scholar
• 18 Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas.  Int J Cancer. 1994;  56 (6) 826-829
  CrossrefPubMedGoogle Scholar
• 19 Fujie T, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Expression of MAGE and BAGE genes in Japanese breast cancers.  Ann Oncol. 1997;  8 (4) 369-372
  CrossrefPubMedGoogle Scholar
• 20 Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli G C, Cerottini J C. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family.  Int J Cancer. 2000;  86 (5) 749-751
  CrossrefPubMedGoogle Scholar
• 21 Magrisso I J, Richmond R E, Carter J H, Pross C B, Gilfillen R A, Carter H W. Immunohistochemical detection of RAS, JUN, FOS, and p 53 oncoprotein expression in human colorectal adenomas and carcinomas.  Lab Invest. 1993;  69 (6) 674-681
  PubMedGoogle Scholar
• 22 Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger A M. FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas.  Breast Cancer Res Treat. 2003;  77 (3) 265-275
  CrossrefPubMedGoogle Scholar
• 23 Teng C S. Protooncogenes as mediators of apoptosis.  Int Rev Cytol. 2000;  197 137-202
  PubMedGoogle Scholar
• 24 Milde-Langosch K. The FOS family of transcription factors and their role in tumourigenesis.  Eur J Cancer. 2005;  41 (16) 2449-2461
  CrossrefPubMedGoogle Scholar

Dr. Joachim Pfannschmidt

Department of Thoracic Surgery
Thoraxklinik am Universitätsklinikum

Amalienstr. 5

69126 Heidelberg

Germany

Phone: + 49 6 22 13 96 11 01

Fax: + 49 6 22 13 96 11 02

Email: joachim.pfannschmidt@thoraxklinik-heidelberg.de